CRANBURY, NJ – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Baraclude® Tablets (Entecavir tablets), 0.5 and 1mg. The product will be available for shipment soon.
Entecavir tablets are used to treat hepatitis B infection.
"We are excited to announce our approval of Entecavir tablets, as well continue to expand our generic product offerings to customers and patients”, said Hai Wang, President of Solco Healthcare.
According to IQVIA, U.S. brand and generic sales of Entecavir tablets were approximately $94.8 million for the 12 months ending in January 2018.